Decitabine and venetoclax after stem cell transplant to prevent relapse
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML), MDS, or a mix called MDS/AML that is considered high-risk for coming back after a stem cell transplant.
- You are at least 18 years old and your overall health is good enough for daily activities (ECOG 0 or 1).
- You will have a stem cell transplant or have already had one within the last 40 days, and your new marrow is working (ANC above 500, platelets above 50,000).
- You do not have active infections, severe graft-versus-host disease (GVHD), or other serious medical problems that would make the trial unsafe.
- Your liver and kidneys are working well enough (bilirubin <2, creatinine clearance >30).
- You have not had your cancer get worse while taking a similar drug (like decitabine or venetoclax) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two cancer medicines—decitabine or azacitidine (also called “hypomethylating agents”) plus venetoclax—given after an allogeneic stem cell transplant to help prevent relapse in people with high-risk AML or MDS. If you have measurable remaining leukemia cells after transplant, this study may be especially relevant.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
This trial tests whether adding venetoclax (a pill) to a lower-intensity bone marrow or stem cell transplant, and continuing it after transplant, helps prevent acute myeloid leukemia (AML) from coming back. You may join if you are in first remission and have a suitable donor.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.